CN106692033A - Blank gel - Google Patents
Blank gel Download PDFInfo
- Publication number
- CN106692033A CN106692033A CN201510782751.8A CN201510782751A CN106692033A CN 106692033 A CN106692033 A CN 106692033A CN 201510782751 A CN201510782751 A CN 201510782751A CN 106692033 A CN106692033 A CN 106692033A
- Authority
- CN
- China
- Prior art keywords
- gel
- blank gel
- blank
- agent according
- cosolvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a blank gel. The blank gel comprises the following components by weight percentage: 5-15% of gel matrix, 1-5% of a transdermal absorption enhancer, 1-5% of a humectant, 0.5-3% of a cosolvent, 0.1-0.5% of a preservative and a proper amount of deionized water. The blank gel is suitable for a water soluble medicine, has the capabilities of bearing and releasing the medicines, meets the requirement of quantitatively adding the ingredients of the medicine conveniently, guarantees stability and uniformity of medicine storage and medicine concentration in the treatment process, is good in stability, and does not mildew or dehydrate easily.
Description
Technical field
The present invention relates to pharmaceutical technology field, spy is related to a kind of Blank gel agent.
Background technology
Ointment is a kind of classical formulation of comparing.Just there are this medicament of ointment in ancient times, have arrived modern development and have gone out transdermal delivery system.
Transdermal delivery system be it is a kind of using skin as administration channel pharmaceutical dosage form, with through skin constant speed, enduringly release medicine enter
The advantages of entering body circulation, avoid medicine from being decomposed in alimentary canal, reduce the infringement to stomach and liver.
Gel in percutaneous drug administration preparation with its transparent appearance, smooth feel and not pollution clothes the advantages of, increasingly receive
Welcome to people.But in general existing water gelling agent easy dehydration and goes mouldy, therefore develop a kind of gel of good stability
Matrix has the meaning of reality.
The content of the invention
Regarding to the issue above, the present invention provides a kind of Blank gel agent, consists of the following components in percentage by weight:Gel-type vehicle
5~15%, skin penetration enhancer 1~5%, NMF 1~5%, cosolvent 0.5~3%, preservative 0.1~0.5%, deionized water
Surplus.
Further, consist of the following components in percentage by weight:Gel-type vehicle 7~12%, skin penetration enhancer 2~4%,
NMF 2~4%, cosolvent 0.8~2%, preservative 0.2~0.4%, deionized water surplus.
Further, consist of the following components in percentage by weight:Gel-type vehicle 10%, skin penetration enhancer 34%, guarantor
Humectant 3%, cosolvent 1%, preservative 0.3%, deionized water surplus.
Specifically, the gel-type vehicle is the one kind in Carbomer, PVPP, Hydroxypropyl methylcellulose.
Specifically, the skin penetration enhancer is peppermint oil and Laurocapram.
Specifically, the cosolvent is glycerine or propane diols.
Specifically, the NMF is hyaluronic acid and chondroitin sulfate.
Specifically, the preservative is the mixed of one or more in ethyl hydroxy benzoate, Phenoxyethanol, methylisothiazolinone
Compound.
Carbomer is the matrix commonly used in water gelling agent, Carbomer to acid, alkali and all certain tolerance of alcohol, low-temperature-resistant and
High pressure moist heat sterilization, there is good biocompatibility, non-stimulated to eye and skin.
Hydroxypropyl methylcellulose is a kind of excellent gel substrate, its preparation process is simple, good stability, good biocompatibility,
Excitant is small, and product is attractive in appearance, it is comfortable to apply exhibition.
Polyvinylpyrrolidone is not involved in human metabolism, and with excellent biocompatibility, to skin, mucous membrane, eye etc.
Any stimulation is not formed.And the action time of medicine can be extended.
Chondroitin sulfate is to be covalently attached the class glycosaminoglycan that proteoglycans is formed on protein.There is protection to collagenous fibres
Effect, with strong water-retaining property, can improve the water metabolism of tissue.
Compared with prior art, Blank gel agent of the invention is aqueous matrix, is suitable for water soluble drug, with carrying and release
The ability of medicine is put, drug ingedient is met and is easy to quantitative addition, it is ensured that the stabilization of medicine reserves, drug concentration over the course for the treatment of
With it is uniform;Good stability, is difficult to go mouldy and dehydration, and walking altering property peppermint oil with fragrance can further increase Transdermal absorption of the present invention
Ability, the addition of chondroitin sulfate enhances the compatibility of preparation and skin histology.
In order to more fully understand and implement, the following detailed description of the present invention.
Specific embodiment
Embodiment 1
Preparation method:Stirring under the Carbomer plus suitable quantity of water normal temperature of formula ratio is taken, is made its swelling and is dissolved;The thin of formula ratio is taken again
Stirring dissolves it under lotus oil, Laurocapram, hyaluronic acid, chondroitin sulfate, glycerine and ethyl hydroxy benzoate add excess water normal temperature,
And in adding to the Carbomer aqueous solution;Plus appropriate triethanolamine adjusts mixed solution pH value to 6.5~7.5, is stirred under normal temperature,
Obtain final product.
Embodiment 2
Preparation method:The lower stirring of PVPP plus suitable quantity of water heating for taking formula ratio makes its dissolving complete;Take again and match somebody with somebody
Peppermint oil, Laurocapram, hyaluronic acid, chondroitin sulfate, propane diols and the Phenoxyethanol that side measures are stirred under adding excess water normal temperature
Mixing dissolves it, and adds to the PVPP aqueous solution, continues to be cooled to normal temperature under stirring, and obtains final product.
Embodiment 3
Preparation method:Taking PVPP plus the suitable quantity of water stirring of formula ratio makes its dissolving complete;Formula ratio is taken again
Stirring makes it under peppermint oil, Laurocapram, hyaluronic acid, chondroitin sulfate, propane diols and Phenoxyethanol add excess water normal temperature
Dissolving, and add to the cross-linked hydroxypropyl methylcellulose aqueous solution, continue to be stirred until homogeneous under normal temperature, obtain final product.
Embodiment 4
Preparation method:Taking PVPP plus the suitable quantity of water stirring of formula ratio makes its dissolving complete;Formula ratio is taken again
Stirring makes it under peppermint oil, Laurocapram, hyaluronic acid, chondroitin sulfate, propane diols and Phenoxyethanol add excess water normal temperature
Dissolving, and add to the cross-linked hydroxypropyl methylcellulose aqueous solution, continue to be stirred until homogeneous under normal temperature, obtain final product.
Embodiment 5
Preparation method:Stirring under the Carbomer plus suitable quantity of water normal temperature of formula ratio is taken, is made its swelling and is dissolved;The thin of formula ratio is taken again
Stirring dissolves it under lotus oil, Laurocapram, hyaluronic acid, chondroitin sulfate, glycerine and ethyl hydroxy benzoate add excess water normal temperature,
And in adding to the Carbomer aqueous solution;Plus appropriate triethanolamine adjusts mixed solution pH value to 6.5~7.5, is stirred under normal temperature,
Obtain final product.
Irritant experiment embodiment
Tested material:Prepare the gained sample of embodiment 1~5 obtained in embodiment
Subject:Totally 36 people, men and women half and half, 20~30 years old age, meets subject's aspiration inclusion criteria.
Test method:Tested material is put into spot examination device, consumption is 0.02g.Control wells are blank (not putting any material).
The back or forearm song side of subject will be pasted on added with the spot of the tested material examination non-stimulated adhesive tape of device, be gently pressed with palm and is allowed to uniform
Be pasted on skin, continue 24h.30min after removal tested material spot examination device, dermoreaction is observed after impression disappears.Such as
Result is feminine gender, is observed again once respectively in 24h after patch test and 48h.By table 3 (skin adverse reaction grade scale table)
Record reaction result.
<The skin adverse reaction grade scale table of table 3>
Result of the test is shown in Table 4:
<Table 4 removes assessment result after tested material>
The result that 24h and 48h are observed again respectively after patch test is with table 4.Result above shows, Blank gel agent of the invention
To the nonirritant effect of human body skin.
Stability experiment embodiment
This is tested with Diclofenac Potassium as model drug, as made by the embodiment 1~5 of the above-mentioned specific embodiment of the present invention
Gel be respectively preformed gel 1~5, commercially available diclofenac potassium gel is control gel, and the present invention is illustrated with experimental result
Technical advantage.
By each one group of sealing of preformed gel 1~5 and control gel, the change for observing gel character at ambient temperature is placed.Knot
Fruit shows that the former can place more than 2 years at room temperature, and the latter places and peptization phenomenon can occur in more than 1 year.By two kinds of gels
Each one group is placed on heating, observed and recorded gel-sol phase transition temperature in water bath.The gel-sol phase of acetonideexample 1~5
Transition temperature is more than 45 DEG C, and control gel is less than 40 DEG C.
Can draw the present invention can make gel stability be improved significantly.
The invention is not limited in above-mentioned implementation method, if not departing from spirit of the invention to various changes of the invention or deformation
And scope, if these are changed and within the scope of deformation belongs to claim of the invention and equivalent technologies, then the present invention is also intended to
Comprising these changes and deformation.
Claims (8)
1. a kind of Blank gel agent, it is characterised in that consist of the following components in percentage by weight:Gel-type vehicle 5~15%, transdermal is inhaled
Receive accelerator 1~5%, NMF 1~5%, cosolvent 0.5~3%, preservative 0.1~0.5%, deionized water surplus.
2. Blank gel agent according to claim 1, it is characterised in that consist of the following components in percentage by weight:Gel base
Matter 7~12%, skin penetration enhancer 2~4%, NMF 2~4%, cosolvent 0.8~2%, preservative 0.2~0.4%, go
Ion water surplus.
3. Blank gel agent according to claim 2, it is characterised in that consist of the following components in percentage by weight:Gel base
Matter 10%, skin penetration enhancer 34%, NMF 3%, cosolvent 1%, preservative 0.3%, deionized water surplus.
4. the Blank gel agent according to claims 1 to 3 any one, it is characterised in that:The gel-type vehicle be Carbomer,
One kind in PVPP, Hydroxypropyl methylcellulose.
5. the Blank gel agent according to claims 1 to 3 any one, it is characterised in that:The skin penetration enhancer is thin
Lotus oil and Laurocapram.
6. the Blank gel agent according to claims 1 to 3 any one, it is characterised in that:The cosolvent is glycerine or the third two
Alcohol.
7. the Blank gel agent according to claims 1 to 3 any one, it is characterised in that:The NMF be hyaluronic acid with
Chondroitin sulfate.
8. the Blank gel agent according to claims 1 to 3 any one, it is characterised in that:The preservative be ethyl hydroxy benzoate,
One or more mixture in Phenoxyethanol, methylisothiazolinone.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510782751.8A CN106692033A (en) | 2015-11-13 | 2015-11-13 | Blank gel |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510782751.8A CN106692033A (en) | 2015-11-13 | 2015-11-13 | Blank gel |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106692033A true CN106692033A (en) | 2017-05-24 |
Family
ID=58930415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510782751.8A Pending CN106692033A (en) | 2015-11-13 | 2015-11-13 | Blank gel |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106692033A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109999205A (en) * | 2019-02-28 | 2019-07-12 | 北京三立慧评化妆品科技有限公司 | Gel combination, patch and its application |
CN110772554A (en) * | 2019-12-05 | 2020-02-11 | 华熙生物科技股份有限公司 | Sodium hyaluronate gel for treating chloasma and preparation method thereof |
CN114848581A (en) * | 2022-04-30 | 2022-08-05 | 辽宁方诺生物科技有限公司 | Berberine hydrochloride sustained-release gel and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1249930A (en) * | 1998-10-07 | 2000-04-12 | 江苏省药物研究所 | Diclofenac potassium gel and ointment and the preparation thereof |
CN101785753A (en) * | 2010-02-04 | 2010-07-28 | 南方医科大学 | Gastrodia elata genin transdermal gel for central nervous system disease treatment |
-
2015
- 2015-11-13 CN CN201510782751.8A patent/CN106692033A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1249930A (en) * | 1998-10-07 | 2000-04-12 | 江苏省药物研究所 | Diclofenac potassium gel and ointment and the preparation thereof |
CN101785753A (en) * | 2010-02-04 | 2010-07-28 | 南方医科大学 | Gastrodia elata genin transdermal gel for central nervous system disease treatment |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109999205A (en) * | 2019-02-28 | 2019-07-12 | 北京三立慧评化妆品科技有限公司 | Gel combination, patch and its application |
CN110772554A (en) * | 2019-12-05 | 2020-02-11 | 华熙生物科技股份有限公司 | Sodium hyaluronate gel for treating chloasma and preparation method thereof |
CN110772554B (en) * | 2019-12-05 | 2021-10-22 | 华熙生物科技股份有限公司 | Sodium hyaluronate gel for treating chloasma and preparation method thereof |
CN114848581A (en) * | 2022-04-30 | 2022-08-05 | 辽宁方诺生物科技有限公司 | Berberine hydrochloride sustained-release gel and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2704703B1 (en) | Transdermal compositions of ibuprofen and methods of use thereof | |
EP3708152B1 (en) | Azelaic acid gel, and preparation method and application thereof | |
CN101288643B (en) | Gel composition containing tacrolimu and its preparation method and medicinal application | |
JP6259454B2 (en) | Diclofenac formulation | |
US20100168200A1 (en) | Antifungal pharmaceutical composition | |
CN105748315B (en) | A kind of composition for repairing skin barrier | |
Alzomor et al. | Formulation and evaluation of potash alum as deodorant lotion and after shaving astringent as cream and gel | |
CN107184427A (en) | A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid | |
CN108836979A (en) | A kind of preparation method of sodium hyaluronate reparation patch and reparation patch and reparation patch Essence | |
CN106619489A (en) | Temperature-sensitive gel for skin injury and preparation method of temperature-sensitive gel | |
Charyulu et al. | Design and evaluation of bigels containing flurbiprofen | |
CN106692033A (en) | Blank gel | |
CN101843637B (en) | External spray for preventing and treating beriberi and preparation method | |
CN108992451A (en) | A kind of emulsifiable paste and preparation method thereof with anti-inflammatory anti-itch antibiotic effect | |
CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
CN102204880A (en) | Disinfectant gellant for gynaecological external use and its preparation method | |
CN110946846B (en) | Loxoprofen sodium gel cream matrix without transdermal penetration enhancer and preparation method thereof | |
CN102657602B (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
CN105963243A (en) | Borneol camphor essential oil slow-release cream for curing acne vulgaris and preparation method thereof | |
WO2020097982A1 (en) | Essential oil composition for scalp care and use | |
CN108653304A (en) | A kind of pterostilbene nano-micelle external-use gel and preparation method thereof | |
CN104274494A (en) | America periplaneta external preparation and preparation method thereof | |
CN110193017A (en) | A kind of spray-filming agent and preparation method thereof promoting hair growth | |
CN103735494B (en) | External antipruritic ointment for treating mosquito bite and preparation method of external antipruritic ointment | |
CN110368453A (en) | A kind of anti-acne thermo-sensitive gel and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |